CNP and achondroplasia: The CNP analogue vosoritide (VO), which is approved for the therapy of achondroplasia, consists of the bioactive fragment CNP-53 with two additional Amino acids at the N-terminus, extending the plasma half-life to approximately 30 min (Fig. 3A) [6].